ChemoMetec enters Letter of Intent with Roche Diagnostics

ANNOUNCEMENT NO. 300

4 February 2026

ChemoMetec enters Letter of Intent with Roche Diagnostics

ChemoMetec has entered a Letter of Intent with Roche Diagnostics aiming to pursue a collaboration with the goal of creating synergies between the parties’ technologies in the field of bioprocess monitoring.

Over the course of 2026 the parties intend to explore and solidify initial ideas of combining the parties’ technologies into validated solutions in the field of bioprocess monitoring, starting with developing a connectivity of ChemoMetec’s XM30 cell counter with Roche’s Cedex Bio Analyzer.

Martin Helbo Behrens, CEO

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.

You May Also Be Interested In

• Arnold Schwarzenegger and Senate Pro Tem Monique Limón team up with AB 32’s Authors to Mark the Law’s 20th Anniversary at the 2026 California Economic Summit
• Paladin Energy Ltd: Quarterly Report for the period ending 30 September 2026
• Plasma Fractionation Market to Reach USD 63.06 Billion by 2031, Driven by Rising Demand for Immunoglobulins and Plasma-Derived Therapies